At a glance
ClinicalIndex Comparison Record- ✓Age ≥18 years
- ✓Asthma diagnosis for ≥6 months
- ✓Clinically stable asthma at enrollment
- ✓Requires ICS treatment per Canadian Asthma Consensus Guidelines
- ✕On combination therapy (ICS + LABA) in past 3 months or requires it
- ✕Severe asthma
- ✕Asthma exacerbation in past 3 months requiring hospitalization or ER visit
- ✕Systemic steroids >3 times in past 6 months or currently using systemic steroids
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-Label Randomized, Multicenter Study in Patients With Asthma to Evaluate the Effectiveness of Alvesco® (Ciclesonide) Compared to Asthma Usual Care in a Primary Practice Setting
In Brief
A Phase 4 clinical trial evaluating Ciclesonide and Usual Care Inhaled Glucocorticosteroids for Asthma. Completed, enrolled 1,121 participants across 186 sites.
Detailed Summary
The purpose of this study is to investigate the effectiveness of Alvesco® (Ciclesonide) compared with usual asthma care in the primary care setting. Patients with a history of asthma for at least 6 months and who, in the opinion of the physician, meet the clinical requirements for treatment with inhaled steroids (ICS) will be enrolled. They will either receive Alvesco® or usual care.
Study Details
Timeline
Interventions
Asthma Care with Alvesco
Usual asthma care and dosage as chosen by the Primary Care Physician including inhaled steroid treatment